Palisade Bio, Inc. financial data

Symbol
PALI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
7750 El Camino Real, Suite 5200, Carlsbad, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Seneca Biopharma, Inc. (to 4/26/2021), Neuralstem, Inc. (to 1/23/2020)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 588 % +21.9%
Debt-to-equity 21.1 % -26.1%
Return On Equity -105 % +9%
Return On Assets -86.9 % +3.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.8M shares +184%
Common Stock, Shares, Outstanding 851K shares -81.3%
Entity Public Float 11.6M USD +43.2%
Common Stock, Value, Issued 8K USD -82.6%
Weighted Average Number of Shares Outstanding, Basic 768K shares +167%
Weighted Average Number of Shares Outstanding, Diluted 768K shares +167%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
General and Administrative Expense 6.12M USD -17%
Operating Income (Loss) -14.2M USD +1.03%
Nonoperating Income (Expense) 727K USD -63%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.5M USD -8.81%
Earnings Per Share, Basic 1.74 USD/shares +43.5%
Earnings Per Share, Diluted 1.74 USD/shares +43.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.3M USD -15.2%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD
Assets, Current 12M USD -16%
Property, Plant and Equipment, Net 5K USD -44.4%
Operating Lease, Right-of-Use Asset 170K USD -38.2%
Other Assets, Noncurrent 438K USD -31.9%
Assets 12.7M USD -17.1%
Accounts Payable, Current 459K USD -35%
Employee-related Liabilities, Current 213K USD +11.5%
Accrued Liabilities, Current 1.67M USD +440%
Liabilities, Current 2.47M USD +87.6%
Operating Lease, Liability, Noncurrent 58K USD -68.1%
Liabilities 2.59M USD +70.8%
Retained Earnings (Accumulated Deficit) -125M USD -212%
Stockholders' Equity Attributable to Parent 10.1M USD -26.8%
Liabilities and Equity 12.7M USD -17.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.18M USD +9.81%
Net Cash Provided by (Used in) Financing Activities 2.02M USD -54.4%
Net Cash Provided by (Used in) Investing Activities -4K USD +60%
Common Stock, Shares Authorized 280M shares 0%
Common Stock, Shares, Issued 851K shares -81.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD -226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2K USD
Deferred Tax Assets, Valuation Allowance 29M USD +8.54%
Deferred Tax Assets, Gross 29.1M USD +8.17%
Operating Lease, Liability 183K USD -37.1%
Depreciation 1K USD 0%
Payments to Acquire Property, Plant, and Equipment 4K USD -60%
Lessee, Operating Lease, Liability, to be Paid 196K USD -40.4%
Operating Lease, Liability, Current 125K USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 59K USD -56.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13K USD -65.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 93K USD
Deferred Tax Assets, Operating Loss Carryforwards 24.7M USD +8.92%
Additional Paid in Capital 135M USD +7.87%
Share-based Payment Arrangement, Expense 626K USD -18.4%
Interest Expense 16K USD +33.3%